Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Volition Veterinary Diagnostics Development LLC Announces Product Data Regarding its Nu.Q Vet Cancer Screening Test in Lymphoma and Hemangiosarcoma to be Presented at the 2020 VCS Virtual Annual Conference

Positive data show high sensitivity and specificity in the detection of Lymphoma and Hemangiosarcoma as Volition remains on target for launch of its first product expected later this year

Cancer is the most common cause of death in dogs over the age of two years old in the U.S.

Together, Lymphoma and Hemangiosarcoma make up approximately one-third of canine cancers

VolitionRx Limited, a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, is presenting two abstracts with new data on its first product, the Nu.Q Vet Cancer Screening Test, at the 2020 Veterinary Cancer Society (VCS) Virtual Annual Conference.

Recommended AI News: Aiforia Secures U.S. Patent For High-Speed AI Training Tool In Medical Image Analysis

Related Posts
1 of 13,909

“The data demonstrate that the Nu.Q Vet Cancer Screening Test has a high sensitivity and specificity in relation to both Lymphoma and Hemangiosarcoma detection in a large and varied cohort,” said Heather Wilson-Robles, Professor at Texas A&M University, Chief Medical Officer of Volition Veterinary Diagnostics Development LLC, and President-Elect of the VCS. “The results show an Area Under the Curve (AUC) of 87.3% and 97.6%, respectively, for Lymphoma and Hemangiosarcoma.

Dr. Robles added, “These positive findings provide us with real confidence as we move forward towards the launch of our first product, the Nu.Q™ Vet Cancer Screening Test, anticipated in the coming weeks. Early diagnosis has a huge potential to help improve the treatment and the quality of life for dogs as well as providing valuable additional information to inform the clinical decision-making process.”

Recommended AI News: Hikvision Releases Colorvu 2.0 Cameras Now With 4k And Varifocal Options

An interview with Heather Wilson-Robles, Chief Medical Officer of Volition Veterinary Diagnostics Development LLC.

Cancer is the most common cause of death in dogs over the age of two years old in the U.S. and up to 50% of all dogs over the age of 10 develop cancer in their lifetime. Together, Lymphoma and Hemangiosarcoma make up approximately one third of canine cancers. Currently, dogs suspected of having cancer are required to undergo a variety of diagnostic tests that may be expensive, time consuming and/or painful for the animal. The Nu.Q Vet Cancer Screening Test is a low-cost, easy to use ELISA-based screening test that measures and identifies circulating nucleosomes, which are early markers of cancer, from a simple blood sample to enable a streamlined and less invasive diagnostic process.

Recommended AI News: Sternum Launches Advanced Detection System For Real-Time Visibility Into Security And Analytics Of IoT Devices

1 Comment
  1. […] Volition Veterinary Diagnostics Development LLC Announces Product Data Regarding its Nu.Q Vet Cancer…  AiThority “lymphoma cancer” – Google News […]

Leave A Reply

Your email address will not be published.